Giredestrant Clinical Trials (2026): 19 Studies for Breast Cancer & Early Breast Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
19 Giredestrant clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 10 indications (including Breast Cancer & Early Breast Cancer) and 10,847 total planned enrollment. 6 Phase 3 Giredestrant trials and 8 Phase 2 are listed. 8 Giredestrant clinical trials are actively recruiting at 82 U.S. sites across 30 states. Most recent activity: NCT07541079 (Jun 2034).
Where to Participate: All Giredestrant Trial Sites in the U.S. (82 sites across 30 states)
Every actively recruiting Giredestranttrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Southern Cancer Center | Daphne36526 | NCT06065748 | Map |
| CA | City of Hope | Duarte91010 | NCT04802759 | Map |
| CA | City of Hope | Duarte91010 | NCT07100106 | Map |
| CA | La Hematology Oncology Medical Group | Glendale91260 | NCT06065748 | Map |
| CA | Marin Cancer Care Inc | Greenbrae94904 | NCT06065748 | Map |
| CA | Kaiser Permanente - Harbor City | Harbor City90710 | NCT06065748 | Map |
| CA | City of Hope - Orange County Lennar Foundation Cancer Center | Irvine92618-2377 | NCT04802759 | Map |
| CA | City of Hope - Orange County Lennar Foundation Cancer Center | Irvine92618 | NCT07100106 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093-1503 | NCT07100106 | Map |
| CA | USC Norris Comprehensive Cancer Center | Los Angeles90033 | NCT06065748 | Map |
| CA | USC Norris Cancer Center | Newport Beach92663 | NCT06065748 | Map |
| CA | UCSF Helen Diller Family CCC | San Francisco94158 | NCT07100106 | Map |
| CA | University of California, San Francisco (UCSF) | San Francisco94143 | NCT04802759 | Map |
| CA | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Santa Monica90404 | NCT04802759 | Map |
| CA | Stanford Cancer Institute (SCI) | Stanford94305 | NCT04802759 | Map |
| CA | The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente | Torrance90502 | NCT06065748 | Map |
| CO | Rocky Mountain Cancer Centers | Littleton80120-4413 | NCT06065748 | Map |
| DC | Georgetown University Medical Center | Washington D.C.20007 | NCT06065748 | Map |
| DC | MedStar Washington Hosp Center | Washington D.C.20010 | NCT06065748 | Map |
| FL | AdventHealth Altamonte | Altamonte Springs32701 | NCT06065748 | Map |
| FL | Florida Cancer Specialists - Broadway | Fort Myers33901 | NCT06065748 | Map |
| FL | Cancer Specialists of North Florida | Jacksonville32256 | NCT06065748 | Map |
| FL | Comprehensive Hematology Oncology | St. Petersburg33709 | NCT06065748 | Map |
| FL | Florida Cancer Specialists - North;725 6th Ave South (St. Petersburg) | St. Petersburg33701-4553 | NCT06065748 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT07100106 | Map |
| FL | Florida Cancer Specialists - EAST - SCRI - PPDS | West Palm Beach33401-3406 | NCT06065748 | Map |
| GA | Grady Health System | Atlanta30303 | NCT06065748 | Map |
| GA | Winship Cancer Institute of Emory University | Atlanta30329 | NCT06065748 | Map |
| GA | Winship Cancer Institute of Emory University | Atlanta30322-1013 | NCT07100106 | Map |
| IL | Advocate Lutheran General Hospital | Park Ridge60068 | NCT06065748 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT06065748 | Map |
| IL | City of Hope® Cancer Center Chicago | Zion60099 | NCT07100106 | Map |
| IA | Mission Cancer + Blood - IMMC | Des Moines50309 | NCT06065748 | Map |
| KY | Baptist Health Hamburg | Lexington40509 | NCT06065748 | Map |
| KY | Baptist Health Lexington | Lexington40503 | NCT06065748 | Map |
| KY | Baptist Health Louisville | Louisville40207 | NCT06065748 | Map |
| ME | Barbara Ann Karmanos Cancer Institute | Detroit48201-2013 | NCT07100106 | Map |
| ME | New England Cancer Specialists | Scarborough04074 | NCT06065748 | Map |
| MD | Maryland Oncology Hematology | Annapolis21401 | NCT06065748 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT06065748 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT04802759 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT06065748 | Map |
| MI | START - Midwest - EDOS | Grand Rapids49546-7062 | NCT07214662 | Map |
| MO | HCA Midwest Division | Kansas City64132 | NCT06065748 | Map |
| MO | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT06065748 | Map |
| MO | Washington University Siteman Cancer Center | St Louis63110-1010 | NCT07100106 | Map |
| NE | Oncology Hematology West - Grand Island | Grand Island68803 | NCT06065748 | Map |
| NE | Oncology Hematology West - Legacy | Omaha68130-2042 | NCT06065748 | Map |
| NJ | Astera Cancer Care East Brunswick | East Brunswick08816 | NCT06065748 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08901-1914 | NCT07100106 | Map |
| NY | New York Cancer & Blood Specialists | East Patchogue11772 | NCT07100106 | Map |
| NY | Queens Hospital Cancer Center | Jamaica11432 | NCT06065748 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT04802759 | Map |
| NC | Duke Women Cancer Care | Raleigh27607 | NCT06065748 | Map |
| OK | University of Oklahoma Health Stephenson Cancer Center | Oklahoma City73104 | NCT04486352 | Map |
| OR | Asante Rogue Regional Medical Center | Medford97504-8332 | NCT06065748 | Map |
| PA | Alliance Cancer Specialists | Bensalem19020 | NCT06065748 | Map |
| PA | Ann B. Barshinger Cancer Institute | Lancaster17604 | NCT06065748 | Map |
| PA | Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit | Philadelphia19106 | NCT06065748 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT04802759 | Map |
| PA | University of Pennsylvania - Abramson Cancer Center | Philadelphia19104 | NCT07100106 | Map |
| PA | UPMC - Hillman Cancer Center | Pittsburgh15213-3108 | NCT07100106 | Map |
| RI | Brown University Health | Providence02905 | NCT06065748 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT06065748 | Map |
| SD | Avera Cancer Institute - Aberdeen | Aberdeen57401 | NCT06065748 | Map |
| SD | Avera Cancer Institute | Sioux Falls57105 | NCT06065748 | Map |
| TN | West Cancer Center | Germantown38138 | NCT04802759 | Map |
| TN | West Cancer Center | Germantown38138 | NCT06065748 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06065748 | Map |
| TN | Vanderbilt Breast Center at One Hundred Oaks | Nashville37204-3609 | NCT07100106 | Map |
| TX | Texas Oncology Cancer Center | Austin78731 | NCT06065748 | Map |
| TX | Texas Oncology (Worth) - USOR | Dallas75246-2003 | NCT07100106 | Map |
| TX | JPS Oncology & Infusion Center | Fort Worth76104 | NCT06065748 | Map |
| TX | Texas Oncology - DFW | Irving75063 | NCT06065748 | Map |
| TX | START - San Antonio - EDOS | San Antonio78229-3307 | NCT07214662 | Map |
| VA | Virginia Cancer Specialists, PC | Fairfax22031 | NCT06065748 | Map |
| VA | Virginia Oncology Associates (Norfolk) - USOR | Norfolk23502-2800 | NCT07100106 | Map |
| VA | Virginia Commonwealth University - Massey Cancer Center | Richmond23219 | NCT06065748 | Map |
| WA | Northwest Medical Specialties | Tacoma98405 | NCT06065748 | Map |
| WV | West Virginia University Hospitals Inc | Morgantown26056 | NCT06065748 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT06065748 | Map |
| WI | Aurora St Lukes Medical Center | Milwaukee53215 | NCT06065748 | Map |
Giredestrant clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | not yet recruiting | Total |
|---|---|---|---|---|---|
| P1 | 1 | 1 | 2 | ||
| P1/P2 | 3 | 3 | |||
| P2 | 2 | 3 | 3 | 8 | |
| P3 | 1 | 4 | 1 | 6 |
Recruiting Giredestrant clinical trials (8)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07541079 | A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) | P3 | Early Breast Cancer | 300 | Jun 2026 |
| NCT07214662 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer | P1 | Breast Cancer | 136 | Jan 2026 |
| NCT04802759 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | P1/P2 | Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | 316 | Jun 2021 |
| NCT06065748 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | P3 | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | 1,050 | Dec 2023 |
| NCT07100106 | MoonROSEA Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | P1/P2 | Breast Cancer | 285 | Oct 2025 |
| NCT05708235 | MiRaDoRA PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population | P2 | Breast Cancer | 976 | Apr 2024 |
| NCT04486352 | EndoMAPA Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | P1/P2 | Endometrial Cancer | 148 | Oct 2021 |
| NCT06259929 | Neo-AGILENEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer | P2 | Breast Cancer | 51 | Jan 2025 |
Giredestrant clinical trials by indication
Breast Cancer (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07214662 | — | P1 | recruiting | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer |
| NCT07100106 | MoonROSE | P1/P2 | recruiting | A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer |
| NCT05708235 | MiRaDoR | P2 | recruiting | A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population |
| NCT06259929 | Neo-AGILE | P2 | recruiting | NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer |
| NCT05896566 | PREcoopERA | P2 | completed | A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer |
| NCT05659563 | EMPRESS | P2 | completed | Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% |
| NCT03916744 | GDC-9545 | P1 | completed | A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer |
Early Breast Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07541079 | — | P3 | not yet recruiting | A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) |
| NCT04961996 | — | P3 | active not recruiting | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) |
| NCT04436744 | — | P2 | completed | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) |
Endometrial Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04486352 | EndoMAP | P1/P2 | recruiting | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer |
| NCT05634499 | EndomERA | P2 | active not recruiting | A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer |
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06065748 | — | P3 | recruiting | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) |
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05306340 | — | P3 | active not recruiting | A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) |
Locally Advanced or Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05296798 | — | P3 | active not recruiting | A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) |
Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04931342 | BOUQUET | P2 | active not recruiting | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors |
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04802759 | — | P1/P2 | recruiting | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer |
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04576455 | — | P2 | active not recruiting | A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) |
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04546009 | — | P3 | active not recruiting | A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) |
Giredestrant pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| MiRaDoR | NCT05708235 | P2 | recruiting | Breast Cancer | 976 | — |
| BOUQUET | NCT04931342 | P2 | active not recruiting | Ovarian Cancer | 176 | — |
| Neo-AGILE | NCT06259929 | P2 | recruiting | Breast Cancer | 51 | — |
| EndomERA | NCT05634499 | P2 | active not recruiting | Endometrial Cancer | 30 | — |
| PREcoopERA | NCT05896566 | P2 | completed | Breast Cancer | 231 | — |
| EMPRESS | NCT05659563 | P2 | completed | Breast Cancer | 92 | — |
All Giredestrant trials (19)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07541079 | A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) | P3 | not yet recruiting | 300 | Genentech, Inc. | Jun 2026 | |
| NCT04961996 | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | P3 | active not recruiting | 4,170 | Hoffmann-La Roche | Aug 2021 | |
| NCT05296798 | A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | P3 | active not recruiting | 922 | Hoffmann-La Roche | Jul 2022 | |
| NCT07214662 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer | P1 | recruiting | 136 | Genentech, Inc. | Jan 2026 | |
| NCT04802759 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | P1/P2 | recruiting | 316 | Hoffmann-La Roche | Jun 2021 | |
| NCT06065748 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | P3 | recruiting | 1,050 | Hoffmann-La Roche | Dec 2023 | |
| NCT07100106 | MoonROSE | A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | P1/P2 | recruiting | 285 | Genentech, Inc. | Oct 2025 |
| NCT05708235 | MiRaDoR | A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population | P2 | recruiting | 976 | MedSIR | Apr 2024 |
| NCT04931342 | BOUQUET | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | P2 | active not recruiting | 176 | Hoffmann-La Roche | Oct 2021 |
| NCT04546009 | A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) | P3 | active not recruiting | 992 | Hoffmann-La Roche | Oct 2020 | |
| NCT04486352 | EndoMAP | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | P1/P2 | recruiting | 148 | Alliance Foundation Trials, LLC. | Oct 2021 |
| NCT04576455 | A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) | P2 | active not recruiting | 303 | Hoffmann-La Roche | Nov 2020 | |
| NCT06259929 | Neo-AGILE | NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer | P2 | recruiting | 51 | Fondazione Oncotech | Jan 2025 |
| NCT05306340 | A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) | P3 | active not recruiting | 373 | Genentech, Inc. | Aug 2022 | |
| NCT05634499 | EndomERA | A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer | P2 | active not recruiting | 30 | Hoffmann-La Roche | Jun 2023 |
| NCT05896566 | PREcoopERA | A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer | P2 | completed | 231 | ETOP IBCSG Partners Foundation | Jan 2024 |
| NCT05659563 | EMPRESS | Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% | P2 | completed | 92 | MedSIR | Jul 2023 |
| NCT04436744 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) | P2 | completed | 221 | Hoffmann-La Roche | Sep 2020 | |
| NCT03916744 | GDC-9545 | A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer | P1 | completed | 75 | Genentech, Inc. | Jul 2019 |
Giredestrant clinical trials: frequently asked questions
- How many Giredestrant clinical trials are there?
- 19 Giredestrant clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 7 are actively recruiting participants. 4 are marked completed.
- Are Giredestrant clinical trials recruiting in 2026?
- Yes — 7 Giredestrant trials are actively recruiting in 2026, with 82 U.S. sites across 30 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Giredestrant being studied for?
- Giredestrant is being studied for Breast Cancer, Early Breast Cancer, Endometrial Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer, Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer and 6 more. The trials are grouped by indication on this page.
- What phase is Giredestrant in?
- Giredestrant clinical trials span 6 Phase 3, 8 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Giredestrant clinical trials?
- The lead sponsor across the most Giredestrant trials is Hoffmann-La Roche, with 5 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Giredestrantas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: